Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC)

• DOI: 10.1016/j.msard.2021.103153
• Publication Date: 2021-07-19T06:05:20Z
• Authors: Sylvia Klineova; Asaff Harel; Rebecca Straus Fa...; Tracy DeAngelis; Yinan Zhang; Roland Hentz; Tung Ming Leung; Kathryn Fong; Tyler Smith; Richard Blanck; Lana Zhovtis-Ryerson
• Keywords: Pandemic; Neuroimmunology; 2019-20 coronavirus outbreak

ObjectiveTo determine outcomes of COVID-19 in patients with Multiple Sclerosis (MS) and related conditions, to predictors these outcomes.MethodsThis was a multicenter, observational cohort study MS or CNS autoimmune disorders who developed confirmed highly suspected infection from 2/1/2020 12/31/2020.Main outcome measureThe primary measure hospitalization status due COVID-19. Severity measured using 4-point ordinal scale: 1. home care; 2. without mechanical ventilation; 3. ventilation, 4. death.ResultsOf 474 the study, 63.3% had 93.9% were diagnosed an phenotype. Mean age 45 ± 13 (mean±SD) years, 72% female, 86% treated DMT at time infection. 58 (12.2%) hospitalized. 24 (5.1%) critically ill (requiring ICU care death), which 15 (3.2%) died. Higher neurological disability older independently predicted hospitalization. 85% (102/120) known antibody results not anti-CD20 therapies seropositive while only 39.5% (17/43) demonstrated seropositivity (p < 0.0001). Only 25% (2/8) PCR-confirmed being seropositivity.ConclusionsNeurological Additionally, demonstrate that significantly blunt humoral responses post-infection, finding carries implications regards natural vaccine-mediated immunity.